Drugs / Buprenorphine/naloxone
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04234191 | Aug 2021 → Jan 2025 | opiate dependence | University of British Columbia | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Buprenorphine/naloxone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04234191 ↗ |
| Known as | Suboxone | “BACKGROUND: Buprenorphine/naloxone (Suboxone) is a current first-line treatment for opioid use disorder (OUD).” PMID 33579359 ↗ Feb 2021 |
| Route | Other | “It is administered via sublingual tablet form.” NCT04234191 ↗ |